Study explains clinical, public health challenges for use of statins in treatment of heart attacks

Charles H. Hennekens, M.D., Dr.P.H., the first Sir Richard Doll professor and senior academic advisor to the dean, and Ira J. Gelb, M.D., emeritus professor of cardiology and senior advisor to the dean for pre-baccalaureate programs at FAU's Charles E. Schmidt College of Medicine, have published an invited editorial in the current issue of Cardiology about the clinical and public health challenges to increase utilization of statins in the treatment and prevention of heart attacks and strokes.

In November 2013, at its national meeting, the American Heart Association, in collaboration with the American College of Cardiology and the United States National Heart, Lung and Blood Institute, presented and published its new guidelines for the use of statins in the treatment and prevention of heart attacks and strokes.

In their invited editorial, Hennekens and Gelb state that any such guidelines are a necessary, but not sufficient basis for the astute clinical judgment of a clinician for each of his or her patients. They provide guiding principles to aid clinicians to make the best judgment about whether to prescribe a statin after consideration of the totality of evidence, which includes the entire risk profile of the patient as well as the benefits and risks of the drug. They re-emphasize that the totality of randomized evidence indicates that there is no threshold for low density lipoprotein cholesterol below which there are no net benefits of statins. These issues in the treatment and prevention of heart attacks and strokes present new and emerging clinical challenges to healthcare providers to more widely prescribe statins in the treatment and prevention of heart attacks and strokes.

"The evidence indicates clearly that the more widespread and appropriate utilization of statins, as adjuncts, not alternatives to therapeutic lifestyle changes, will yield net benefits in the treatment and prevention of heart attacks and strokes, including among high, medium and low risk patients unwilling or unable to adopt therapeutic lifestyle changes," said Hennekens.

According to the Centers for Disease Control and Prevention, heart disease is the leading killer among U.S. men and women, causing approximately 600,000 deaths each year.

In 2012, Science Heroes ranked Hennekens No. 81 in the history of the world for having saved more than 1.1 million lives. From 1995-2005, Science Watch ranked Hennekens as the third most widely cited medical researcher in the world, and five of the top 20 were his former trainees and/or fellows.


Florida Atlantic University


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
Nanoparticles can travel from the lungs into bloodstream and reach susceptible areas of cardiovascular system